-
公开(公告)号：US20180362502A1
公开(公告)日：2018-12-20
申请号：US15988783
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D513/04 , C07D491/08 , C07D487/08
CPC classification number: C07D401/14 , C07D417/14 , C07D487/08 , C07D491/08 , C07D513/04
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10149835B2
公开(公告)日：2018-12-11
申请号：US15597431
申请日：2017-05-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Xuechao Xing , Ruichao Shen , Bin Wang , Brett Granger , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC: A61K31/42 , C07D225/04 , C07D213/127 , C07D261/08 , C07C317/38
Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.
-
公开(公告)号：US10080743B2
公开(公告)日：2018-09-25
申请号：US15497359
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Bin Wang , Xuechao Xing , Ruichao Shen , Brett Granger , Jun Ma , Jing He , Yong He , Jiang Long , Guoqiang Wang
IPC: C07D261/08 , C07D413/12 , A61K31/42 , A61K31/422
CPC classification number: A61K31/42 , A61K31/422 , C07D261/08 , C07D413/12
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20180141941A1
公开(公告)日：2018-05-24
申请号：US15793554
申请日：2017-10-25
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Jing He , Guoqiang Wang , Ruichao Shen , Xuechao Xing , Bin Wang , Jun Ma , Yat Sun Or
CPC classification number: C07D451/02 , A61P1/00 , A61P1/16 , A61P3/00 , A61P9/00 , A61P11/00 , A61P13/12
Abstract: The present invention provides compounds of Formula I, Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
15.发明申请Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof 审中-公开胆酸衍生物作为FXR / TGR5激动剂及其使用方法公开(公告)号：US20160176917A1
公开(公告)日：2016-06-23
申请号：US14976294
申请日：2015-12-21
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
CPC classification number: C07J43/003 , C07J41/0055 , C07J41/0088
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
Abstract translation: 本发明提供式I化合物，包含这些化合物的药物组合物以及使用这些化合物预防或治疗FXR介导的或TGR5介导的疾病或病症的方法。
-
Patent Agency Ranking
16.发明公开公开(公告)号：US20240228464A9
公开(公告)日：2024-07-11
申请号：US18383949
申请日：2023-10-26
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).-
公开(公告)号：US11034684B2
公开(公告)日：2021-06-15
申请号：US16569819
申请日：2019-09-13
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Jun Ma , Guoqiang Wang , Bin Wang , Xuechao Xing , Ruichao Shen , Jing He , Yat Sun Or
IPC: C07D417/14 , C07D413/14 , C07D261/08 , C07D413/12
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
18.发明授权公开(公告)号：US11008304B2
公开(公告)日：2021-05-18
申请号：US16400529
申请日：2019-05-01
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
-
公开(公告)号：US10683289B2
公开(公告)日：2020-06-16
申请号：US16400498
申请日：2019-05-01
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jing He , Yat Sun Or
IPC: C07D417/14 , A61K31/4164 , A61K31/4196 , A61K31/4439
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).
-
公开(公告)号：US20200157095A1
公开(公告)日：2020-05-21
申请号：US16688429
申请日：2019-11-19
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jing He , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D471/04 , C07D401/14 , C07D413/14 , C07D405/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
-
-
-
-
-
-
-
-
Search Results
72
records
(took 0.03 seconds)
